Answers are grounded in this paper and cite their sources.
Aim: The aim of the present study was to investigate whether oral administration of labetalol, an αβ-blocker, might be useful for managing blood pressure (BP) in women with severe pregnancy induced hypertension (PIH).Methods: Thirty-four pregnant women with severe hypertension (≥160/110 mmHg) were enrolled (15 preeclampsia [PE] and 19 gestational hypertension [GH]). Labetalol was given orally at 300–400 mg daily, and mean arterial pressure (MAP), the numeric rating scale (NRS) for headache, the double product (DP) as a work index of cardiac function, and fetal heart monitoring were observed for 3 days.Results: Thirty patients continued to take labetalol for 3 days. Four PE patients were dropped out. Fifteen showed a decrease of more than 10% in MAP and were considered responders, while 19 showed a decrease of less than 10% and were considered non-responders. Labetalol appeared to be more effective in GH (11/19) than in PE (4/15). The NRS was improved in both groups (6 PE and 7 GH), as was DP (13 GH and 8 PE). Unfavorable changes in fetal heart rates were seen in 3 (1 PE and 2 GH).Conclusion: The oral administration of labetalol might control the hypertension as well as the clinical symptoms in GH.
No takes yet. Share an insight, caveat, or question.
Matsuura et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: